1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Applied BioCode Corp.

Applied BioCode Corp.

TTWSE:6598
30.30
TWD
0.00
(0.00%)
-0.47EPS
2.35BMarket Cap
Nov 05Next Earn
Applied BioCode Corp.
TWSE:6598
(Taiwan Stock Exchange)

Recent

price

30.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
- -
1.16
0.6
- -
0.25
0.54
0.66
1.54
3.64
3.7
4.51
4.83
3.79
4.62
6.45
Revenue per Share
- -
-9.1
-2.82
- -
-2.94
-5.34
-4.79
-4.12
-1.26
-1.91
-2.14
-2.01
-2.88
-1.96
-0.47
Basic EPS, GAAP
- -
-4.57
-5.32
- -
-4.03
-5.19
-5.45
-4.97
-2.13
-1.94
1.43
-2.59
-2.37
-2.29
-0.9
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
8.64
6.07
11.22
- -
8.5
5.1
6.58
6.94
12.58
10.44
9.43
7.64
8.55
6.26
6.82
Book Value per Share
7.34
4.85
10.04
- -
7.94
4.68
6.18
6.65
12.38
10.29
9.31
7.57
8.53
6.26
6.82
Tangible Book Value per Share
28
23
25
31
46
49
56
68
82
86
87
82
91
103
103
Basic Weighted Avg Shares
- -
27
15
- -
12
27
37
105
299
320
390
395
343
475
667
Sales/Revenue/Turnover
- -
-313.15
-1,071.91
- -
-1,654.46
-986.13
-725.88
-262.74
-44.65
-51.55
-49.25
-47.17
-80.94
-46.89
-9.47
Operating Margin (%)
- -
5
7
- -
11
13
17
33
44
51
57
63
61
56
54
Depreciation Expense
- -
-208
-71
- -
-136
-263
-268
-280
-103
-165
-185
-164
-261
-201
-49
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-781.47
-468.64
- -
-1,155.41
-984.68
-727.04
-267.52
-34.61
-51.63
-47.33
-41.55
-76.02
-42.34
-7.33
Profit Margin (%)
176
64
247
- -
370
239
368
428
943
766
927
736
974
732
805
Working Capital
- -
- -
- -
- -
- -
- -
- -
63
49
45
33
18
2
39
31
LT Debt
243
171
316
- -
428
277
433
531
1,087
903
816
661
879
643
702
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-100.51
-29.25
- -
-63.55
-74.83
-75.66
-58.14
-12.8
-16.6
-21.49
-22.23
-33.87
-26.44
-6.93
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
21
20
21
LT Borrowings
- -
- -
- -
LT Finance Leases
39
36
31
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
103
103
103
Market Capitalization
2,262
2,329
2,349

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
858
947
934
Cash, Cash Equivalents & STI
570
542
557
Accounts Receivable, Net
122
201
161
Inventories
156
193
203
Total Current Liabilities
127
157
129
Payables & Accruals
- -
- -
- -
ST Debt
21
20
21
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-7.88%
-26.81%
Free Cash Flow
- -
-87.44%
9.46%
Net Income, GAAP
- -
19.26%
-22.85%
Sales/Revenue/Turnover
- -
11.12%
38.52%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
82
102
75
85
343
2025
120
116
123
116
475
2026
217
210
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.77
-0.61
-0.8
-0.69
-2.88
2025
-0.35
-0.66
-0.33
-0.63
-1.96
2026
0.2
0.27
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Applied BioCode Corporation (6598.TW) develops and manufactures multiplex testing platforms and diagnostic assays for infectious diseases, autoimmune disorders, and genetic analysis. The company offers the BioCode 100 MDx system, a fully automated magnetic bead-based platform supporting up to 384-plex testing per well with chemiluminescence detection; BARCODE multiplex immunoassays covering over 100 tests for respiratory viruses, gastrointestinal pathogens, transplant monitoring, and neurology markers; and molecular diagnostic kits utilizing its proprietary MDx 3000 instrument for high-throughput PCR-based detection. Products are distributed through partnerships in clinical laboratories, hospitals, and research institutions primarily in Asia, North America, and Europe. Founded in 2005 and headquartered in Santa Fe Springs, California, USA, with manufacturing and R&D facilities in Taiwan. In late 2024, Applied BioCode expanded its BARCODE Allergy panel with 44 new tests for food and inhalant allergens, enhancing its immunology portfolio; secured a strategic distribution agreement with Sequel Med Tech in Europe for MDx products; and reported record revenue growth driven by U.S. FDA clearance for additional respiratory panels amid heightened demand for multiplex diagnostics.